Biodexa Pharmaceticals

Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing treatments for familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and rare/orphan brain cancers. Its lead candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is in Phase II studies for Type 1 diabetes. The company is also developing MTX110 in Phase I studies for recurrent glioblastoma, diffuse midline glioma, and medulloblastoma, and MTX240 for gastrointestinal stromal tumors. It offers drug delivery platforms including Q-Sphera, MidaSolve, and MidaCore, and has collaboration agreements with Janssen and Melior. Formerly known as Midatech Pharma plc, it changed its name to Biodexa Pharmaceuticals Plc in March 2023. Founded in 2000, it is headquartered in Cardiff, United Kingdom.